mutational landscape lethal castration-resistant prostate cancer 
characterization prostate cancer transcriptome genome identified chromosomal rearrangements copy number gains losses including ets gene family fusions pten loss androgen receptor ar amplification drive prostate cancer development progression lethal metastatic castration-resistant prostate cancer crpc1 however less known role mutations2- sequenced exomes lethal heavily pre-treated metastatic crpcs obtained rapid autopsy including three different foci patient treatment-naive high-grade localized prostate cancers identified low overall mutation rates even heavily treated crpcs per megabase confirmed monoclonal origin lethal crpc integrating exome copy number analysis identified disruptions chd1 define subtype ets gene family fusion-negative prostate cancer similarly demonstrate ets2 deleted approximately one-third crpcs commonly tmprss2:erg fusions also deregulated mutation furthermore identified recurrent mutations multiple chromatin histone-modifying genes including mll2 mutated % prostate cancers demonstrate interaction mll complex ar required ar-mediated signalling also identified novel recurrent mutations ar collaborating factor foxa1 mutated % prostate cancers untreated localized prostate cancer crpc showed mutated foxa1 represses androgen signalling increases tumour growth proteins physically interact ar erg gene fusion product foxa1 mll2 utx also known kdm6a asxl1 found mutated crpc summary describe mutational landscape heavily treated metastatic cancer identify novel mechanisms ar signalling deregulated prostate cancer prioritize candidates future study 
